Ginkgo Bioworks handed a DARPA manufacturing contract; Merck hits a primary endpoint for Keytruda in first-line cervical cancer

The De­fense Ad­vanced Re­search Projects Agency (DARPA) is giv­ing Gink­go Bioworks a 4-year con­tract worth up to $18 mil­lion, to man­u­fac­ture com­plex ther­a­peu­tic pro­teins.

Gink­go is part of DARPA’s “Reimag­in­ing Pro­tein Man­u­fac­tur­ing project,” which is de­signed to help the DOD get ac­cess to pro­teins more quick­ly. Gink­go plans to man­u­fac­ture pro­teins faster by us­ing its “cell-free pro­tein syn­the­sis to en­able rapid, high-yield” pro­duc­tion of pro­teins for na­tion­al se­cu­ri­ty ini­tia­tives.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN